Quantitation of ivosidenib in human plasma via LC-MS/MS and its application in clinical trials
Feng Yin1, Shaoxia Yu1, Rohini Narayanaswamy1
1Agios Pharmaceuticals Inc., 88 Sidney Street, Cambridge, MA 02139, USA.
Abstract:
Aim: Ivosidenib is a potent and selective small molecule inhibitor of mutant isocitrate dehydrogenase 1. Accurate measurement of ivosidenib is the key to ivosidenib pharmacokinetics in clinical trials. Materials & methods: Quantitation of ivosidenib was conducted by using a stable isotope labeled compound (ivosidenib-d4) as the internal standard. Results: This assay was validated and successfully applied to support multiple clinical trials. Selected clinical samples were also tested by a chiral LC-MS/MS method against four ivosidenib isomer standards to exclude the possibility of in vivo racemization of ivosidenib. Conclusion: A robust LC-MS/MS method was validated for ivosidenib in human plasma. This is the first time for ivosidenib bioanalytical method in any human matrix to be reported.
More Related Videos
10:38Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
Published on: May 9, 2020
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Related Concept Videos
Therapeutic Drug Monitoring: Drug Analysis Methods
Measurement of Bioavailability: Pharmacodynamic Methods
Measurement of Bioavailability: Pharmacokinetic Methods
Drug Product Performance: In Vitro–In Vivo Correlation
Inductively Coupled Plasma–Mass Spectrometry (ICP–MS): Overview
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
